Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Interleukin-17A (IL-17A): A silent amplifier of COVID-19.
Maione, Francesco; Casillo, Gian Marco; Raucci, Federica; Salvatore, Cristian; Ambrosini, Giovanna; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria.
Biomed Pharmacother ; 142: 111980, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1330664

ABSTRACT

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Cytokine Release Syndrome , Interleukin-17 , Biomarkers/blood , COVID-19/diagnosis , COVID-19/immunology , Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/immunology , Disease Progression , Drug Discovery , Humans , Inflammation Mediators/metabolism , Interleukin-17/blood , Interleukin-17/immunology , Severity of Illness Index
2.
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Casillo, Gian Marco; Mansour, Adel Abo; Raucci, Federica; Saviano, Anella; Mascolo, Nicola; Iqbal, Asif Jilani; Maione, Francesco.
Pharmacol Res ; 156: 104791, 2020 06.
Article in English | MEDLINE | ID: covidwho-208932

Subject(s)
Betacoronavirus , Coronavirus Infections/drug therapy , Interleukin-17/immunology , Pneumonia, Viral/drug therapy , COVID-19 , Coronavirus Infections/immunology , Humans , Pandemics , Pneumonia, Viral/immunology , SARS-CoV-2 , COVID-19 Drug Treatment
3.
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.
Raucci, Federica; Mansour, Adel Abo; Casillo, Gian Marco; Saviano, Anella; Caso, Francesco; Scarpa, Raffaele; Mascolo, Nicola; Iqbal, Asif Jilani; Maione, Francesco.
Autoimmun Rev ; 19(7): 102572, 2020 07.
Article in English | MEDLINE | ID: covidwho-155059

Subject(s)
Coronavirus Infections/immunology , Endothelium, Vascular/physiopathology , Interleukin-17/immunology , Pneumonia, Viral/immunology , Thrombosis/physiopathology , Adaptive Immunity , Betacoronavirus , COVID-19 , Coronavirus Infections/physiopathology , Humans , Immunity, Innate , Pandemics , Pneumonia, Viral/physiopathology , SARS-CoV-2
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL